Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.
Explainers in 2026
Page 2 of 3 of this archive, newest first.
Nought point nine eight of a dalton: the modification that hides in plain sight
What would be needed to catch each of these, and what it would cost.
Why VendorInvestigate can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
The mechanism behind the mechanism
Delayed gastric emptying is a mechanism that becomes an adverse effect above a threshold. It is not a complication in the ordinary sense.
What a month without the drug does to tolerability
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
One receptor, several signals: the case for reading liraglutide as a biased agonist
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
A named analyst is the cheapest quality signal in this trade
Somebody has to be answerable for a release document. On most certificates in this market, nobody is named at all.
The same signature, the same peak, three different batches
A blank certificate with the numbers left editable is an ordinary internal document. Its circulation as a finished record is the problem.
Reading the mazdutide titration schedule as a regulatory artefact
What the regulatory dossiers actually contain on dose selection is remarkably thin, and worth knowing before treating the ladder as settled science.
The chromatogram that appears on four documents
A PDF carries metadata about the software that produced it, and that metadata is frequently more informative than the content.
Dose-limiting: a definition worth being strict about
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
Accreditation, scope, and the question nobody asks VendorInvestigate
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
What the trials adjudicated, and how
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Reading the receptor: what distinguishes survodutide from liraglutide at the molecular level
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
A percentage is not a specification
This piece takes the measurement apart into the decisions it is made of, because each decision moves the answer.
Reading the survodutide titration schedule as a regulatory artefact
What the regulatory dossiers actually contain on dose selection is remarkably thin, and worth knowing before treating the ladder as settled science.
Dose-limiting: a definition worth being strict about
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
An error taxonomy for a market without a pharmacist
The recurring errors in this market are not exotic. They are a small set of arithmetic and reading failures, each capable of moving a dose by a factor of two or ten.
The interventions with trial support, and the much longer list without
Constipation is the most tractable of the effects and the most consistently under-managed.